Table 3.
Aberrant expression of iP and cP subunits
| Cell lines | Expression | Fold difference (cell viability) | Ref. |
|---|---|---|---|
| RAJI DG75 KARPAS442 |
↓ β2, β1i ↓ β2i (KARPAS442 & DG75 only) |
Selected at 10–40 nM bortezomib | Busse et al.[53] |
| RPMI 8226 CCRF-CEM THP1 |
↓ β1i, β2i, β5i ↑ β1, β2, β5 |
~40–150 | Niewerth et al.[23] |
| Namalwa (MES-SA) | ↓ β1i, β2i, β5i ↑ β1, β2, β5 |
Growing at 12.5 nM of bortezomib | Fuchs et al.[71] |
| Primary bone marrow plasma cells | ↑ β5i | After carfilzomib therapy | Woodle et al.[55] |
↑: increased; ↓: decreased.